AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35614405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided evacuation
Number of subjects: 315
Study 35614405 — intervention group
Group type: COMPARATOR
Intervention: Blind surgical evacuation
Number of subjects: 315
Study 33609960 — intervention group
Group type: EXPERIMENTAL
Intervention: DOMS-inducing exercise protocol
Number of subjects: 32
Study 33609960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DOMS-inducing exercise protocol)
Number of subjects: 32
Study 33040573 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective testing (add-on test results with interpretative comments)
Number of subjects: 270
Study 33040573 — intervention group
Group type: COMPARATOR
Intervention: Standard laboratory test results only (control group)
Number of subjects: 270
Study 32593046 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-plant extract BNO 1012 in addition to standard symptomatic therapy
Number of subjects: 292
Study 32593046 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 292
Study 33301004 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 0
Study 33301004 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides
Number of subjects: 0
Study 33301004 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0
Study 32400350 — intervention group
Group type: EXPERIMENTAL
Intervention: Operational research approaches and methodologies used by SCORE.
Number of subjects: 0
Study 32400350 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cluster-randomized trials conducted by SCORE.
Number of subjects: 0
Study 32400350 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with stakeholders and sectors in endemic countries.
Number of subjects: 0
Study 32768592 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab induction with low dose steroids and MMF, delayed introduction of CNI (n=42)
Number of subjects: 89
Study 32768592 — intervention group
Group type: COMPARATOR
Intervention: Standard triple immunosuppression (steroid, tacrolimus, and mycophenolate mofetil) (n=47)
Number of subjects: 89
Study 32768592 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab induction
Number of subjects: 89
Study 32768592 — intervention group
Group type: COMPARATOR
Intervention: Standard triple immunosuppression
Number of subjects: 89
Study 35499569 — intervention group
Group type: EXPERIMENTAL
Intervention: TRX518 monotherapy
Number of subjects: 109
Study 35499569 — intervention group
Group type: EXPERIMENTAL
Intervention: TRX518 in combination with gemcitabine (Part C)
Number of subjects: 109
Study 35499569 — intervention group
Group type: EXPERIMENTAL
Intervention: TRX518 in combination with pembrolizumab (Part D)
Number of subjects: 109
Study 35499569 — intervention group
Group type: EXPERIMENTAL
Intervention: TRX518 in combination with nivolumab (Part E)
Number of subjects: 109
Study 35499569 — intervention group
Group type: EXPERIMENTAL
Intervention: TRX518 monotherapy + anti-PD1 combination
Number of subjects: 109
Study 32829400 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 2044848
Study 32829400 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination at birth (control group)
Number of subjects: 2044848
Study 32809025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0
Study 32809025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33822027 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy force (H, 500 g)
Number of subjects: 40
Study 33822027 — intervention group
Group type: COMPARATOR
Intervention: Light force (L, 300 g)
Number of subjects: 40
Study 33553097 — intervention group
Group type: EXPERIMENTAL
Intervention: Campylobacter colonization
Number of subjects: 102
Study 33553097 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Enteric Dysfunction (EED)
Number of subjects: 102
Study 33553097 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting
Number of subjects: 102
Study 33553097 — intervention group
Group type: EXPERIMENTAL
Intervention: Current breastfeeding and ASF consumption
Number of subjects: 102
Study 33553097 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved drinking water supply
Number of subjects: 102
Study 33553097 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for stunting
Number of subjects: 102
Study 35866201 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge SAM relapse
Number of subjects: 1490
Study 35866201 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge hospitalisation
Number of subjects: 1490
Study 35866201 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge during the lean season
Number of subjects: 1490
Study 35866201 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger household size
Number of subjects: 1490
Study 35866201 — intervention group
Group type: EXPERIMENTAL
Intervention: Older child age
Number of subjects: 1490
Study 35866201 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher child MUAC at discharge
Number of subjects: 1490
Study 35866201 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal literacy
Number of subjects: 1490
Study 33942778 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Number of subjects: 30
Study 33942778 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation mode
Number of subjects: 30
Study 34151973 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal MMS
Number of subjects: 8428
Study 34151973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8428
Study 34151973 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal MMS
Number of subjects: 8428
Study 34151973 — intervention group
Group type: COMPARATOR
Intervention: Postnatal Placebo
Number of subjects: 8428
Study 33156550 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 167
Study 33156550 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily
Number of subjects: 167
Study 33156550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 35226949 — intervention group
Group type: EXPERIMENTAL
Intervention: ReWin(d) supplement
Number of subjects: 34
Study 35226949 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 34
Study 33977377 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic camera control
Number of subjects: 100
Study 33977377 — intervention group
Group type: COMPARATOR
Intervention: Human camera control
Number of subjects: 100
Study 34792542 — intervention group
Group type: COMPARATOR
Intervention: OTTO approach (6 weeks of no treatment followed by 6 weeks of OTTO)
Number of subjects: 14
Study 34792542 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotic intervention (6 weeks of orthotic intervention followed by 6 weeks of orthosis plus OTTO)
Number of subjects: 14
Study 32333897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg every 4 weeks)
Number of subjects: 118
Study 32333897 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2‐3 mg/kg per day)
Number of subjects: 118
Study 33686788 — intervention group
Group type: EXPERIMENTAL
Intervention: Time for Dementia programme
Number of subjects: 386
Study 33686788 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal curriculum)
Number of subjects: 386
Study 33049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions
Number of subjects: 0
Study 33049706 — intervention group
Group type: COMPARATOR
Intervention: Isotonic contractions
Number of subjects: 0
Study 35872131 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive discectomy
Number of subjects: 222
Study 33875277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance Induction (DI)
Number of subjects: 1517
Study 33875277 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment Reactivity (AR)
Number of subjects: 1517
Study 33875277 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1517
Study 32696273 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-distribution based approach
Number of subjects: 0
Study 32696273 — intervention group
Group type: EXPERIMENTAL
Intervention: CUB (combined uniform and binomial)
Number of subjects: 0
Study 35879059 — intervention group
Group type: EXPERIMENTAL
Intervention: Goodmorning S Granule®
Number of subjects: 50
Study 35879059 — intervention group
Group type: COMPARATOR
Intervention: Bisacodyl
Number of subjects: 50
Study 34960007 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum plasmalogen dm16:0
Number of subjects: 522
Study 34960007 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated odd-chain FA 15.0 (pentadecanoic acid)
Number of subjects: 522
Study 34960007 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 very long-chain FAs
Number of subjects: 522
Study 34960007 — intervention group
Group type: COMPARATOR
Intervention: High serum triglycerides
Number of subjects: 522
Study 32736776 — intervention group
Group type: COMPARATOR
Intervention: Lymphoma patients
Number of subjects: 449
Study 32736776 — intervention group
Group type: COMPARATOR
Intervention: Metastatic solid organ disease patients
Number of subjects: 449
Study 33946137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL hydro-alcoholic extract of Morus nigra leaves, three times a day
Number of subjects: 100
Study 33946137 — intervention group
Group type: COMPARATOR
Intervention: Placebo in water, three times a day
Number of subjects: 100
Study 34281811 — intervention group
Group type: EXPERIMENTAL
Intervention: Researching Eating, Activity, and Cognitive Health (REACH) Study food frequency questionnaire (FFQ)
Number of subjects: 294
Study 33246911 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), taken thrice-weekly for 18 months
Number of subjects: 221
Study 33246911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 32966830 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy
Number of subjects: 333
Study 32966830 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 333
Study 36121652 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 1.7‐mg semaglutide subcutaneous injections for 3 to 6 months
Number of subjects: 408
Study 36121652 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 2.4‐mg semaglutide subcutaneous injections for 3 to 6 months
Number of subjects: 408
Study 36121652 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly semaglutide treatment
Number of subjects: 408
Study 33711671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI (5 mg/kg every 2 weeks)
Number of subjects: 240
Study 33711671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (400 mg/m2 then 250 mg/m2 weekly)
Number of subjects: 240
Study 33711671 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 240
Study 33711671 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 240
Study 33711671 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF/PIK3CA-mutated tumours
Number of subjects: 240
Study 33012870 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 1357
Study 33012870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1357
Study 35224682 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (20 min, two sessions per week for 8 weeks)
Number of subjects: 30
Study 35224682 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy after BoNT‐A injection
Number of subjects: 30
Study 33482878 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint herbal plaster (AHP)
Number of subjects: 166
Study 33482878 — intervention group
Group type: COMPARATOR
Intervention: Acupoint placebo plaster (APP)
Number of subjects: 166
Study 35730342 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol/urea 20% (Group D)
Number of subjects: 60
Study 35730342 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (Group C)
Number of subjects: 60
Study 35730342 — intervention group
Group type: COMPARATOR
Intervention: Intralesional methotrexate (Group B)
Number of subjects: 60
Study 35730342 — intervention group
Group type: COMPARATOR
Intervention: Intralesional 5-fluorouracil (Group A)
Number of subjects: 60
Study 33002792 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based remote rehabilitation project after discharge
Number of subjects: 61
Study 33002792 — intervention group
Group type: COMPARATOR
Intervention: Regular telephone follow-up after discharge
Number of subjects: 61
Study 33289528 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group)
Number of subjects: 933
Study 33289528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scratch)
Number of subjects: 933
Study 33289528 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group) after 12 months
Number of subjects: 933
Study 33289528 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group) biochemical pregnancy loss
Number of subjects: 933
Study 33289528 — intervention group
Group type: COMPARATOR
Intervention: Control group biochemical pregnancy loss
Number of subjects: 933
Study 33289528 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group) miscarriage rate
Number of subjects: 933
Study 33289528 — intervention group
Group type: COMPARATOR
Intervention: Control group miscarriage rate
Number of subjects: 933
Study 33038157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold riboflavin (4°C)
Number of subjects: 98
Study 33038157 — intervention group
Group type: COMPARATOR
Intervention: Control group (riboflavin at room temperature)
Number of subjects: 98
Study 616497225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab targeting therapy
Number of subjects: 92
Study 616497225 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen with oxaliplatin, calcium folinate and 5-fluorouracil (Control)
Number of subjects: 92
Study 34783447 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow Yeast Rice (YYR) supplementation
Number of subjects: 0
Study 33795720 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (SA)
Number of subjects: 80458
Study 33795720 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 80458
Study 32349765 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT)
Number of subjects: 105
Study 32349765 — intervention group
Group type: COMPARATOR
Intervention: Negative control (pooled sera from malaria naïve participants)
Number of subjects: 105
Study 34028298 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR plus bandage
Number of subjects: 74
Study 34028298 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with bandage treatment
Number of subjects: 74
Study 33025679 — intervention group
Group type: EXPERIMENTAL
Intervention: High sitters
Number of subjects: 172
Study 33025679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sleepers
Number of subjects: 172
Study 33025679 — intervention group
Group type: EXPERIMENTAL
Intervention: High sleepers
Number of subjects: 172
Study 33025679 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced activity
Number of subjects: 172
Study 33025679 — intervention group
Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 172
Study 33025679 — intervention group
Group type: COMPARATOR
Intervention: Weaker occupational sitting habit
Number of subjects: 172
Study 33025679 — intervention group
Group type: COMPARATOR
Intervention: Stronger walking outside habit
Number of subjects: 172
Study 35648242 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 1067
Study 35648242 — intervention group
Group type: COMPARATOR
Intervention: Non-febuxostat
Number of subjects: 1067
Study 35648242 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (40 mg)
Number of subjects: 1067
Study 33592205 — intervention group
Group type: EXPERIMENTAL
Intervention: Early peanut consumption
Number of subjects: 341
Study 33592205 — intervention group
Group type: COMPARATOR
Intervention: Avoiding peanut
Number of subjects: 341
Study 34656771 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-trimester ultrasound with measurement of lower uterine segment thickness (LUST) and estimation of fetal weight (EFW)
Number of subjects: 2705
Study 34656771 — intervention group
Group type: COMPARATOR
Intervention: No third-trimester ultrasound with measurement of lower uterine segment thickness (LUST) and estimation of fetal weight (EFW)
Number of subjects: 2705
Study 34301661 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of prescription charges for 12 months
Number of subjects: 2000
Study 34301661 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2000
Study 32237005 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics-based telehealth intervention (up to $50 per month for daily adherence, $2 deduction for missed doses)
Number of subjects: 130
Study 32237005 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 130
Study 32237005 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics-based telehealth intervention
Number of subjects: 130
Study 33448327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge regression screening procedure
Number of subjects: 0
Study 33448327 — intervention group
Group type: COMPARATOR
Intervention: Traditional one-biomarker-at-a-time screening procedure
Number of subjects: 0
Study 34077644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted NmCV‐5
Number of subjects: 376
Study 34077644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum‐adjuvanted NmCV‐5
Number of subjects: 376
Study 34077644 — intervention group
Group type: COMPARATOR
Intervention: MenACWY‐D
Number of subjects: 376
Study 35229554 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) during PCI
Number of subjects: 30
Study 35229554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 30
Study 34842524 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard care plus social recovery therapy
Number of subjects: 270
Study 34842524 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care alone
Number of subjects: 270
Study 33549776 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS II block
Number of subjects: 0
Study 33549776 — intervention group
Group type: COMPARATOR
Intervention: Non-block
Number of subjects: 0
Study 32000559 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized follow-up care with ePROs
Number of subjects: 134
Study 32000559 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 134
Study 33232739 — intervention group
Group type: EXPERIMENTAL
Intervention: Drifting ambient temperature (17–25°C with a morning ramp of 2.58°C/h and afternoon ramp of ‐2.58°C/h)
Number of subjects: 16
Study 33232739 — intervention group
Group type: COMPARATOR
Intervention: Fixed ambient temperature (21°C)
Number of subjects: 16
Study 32844495 — intervention group
Group type: EXPERIMENTAL
Intervention: Logarithmic scale for COVID-19 related deaths
Number of subjects: 0
Study 32844495 — intervention group
Group type: COMPARATOR
Intervention: Linear scale for COVID-19 related deaths
Number of subjects: 0
Study 36097940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1SiO2‐1ZrO2
Number of subjects: 140
Study 36097940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1SiO2‐2ZrO2
Number of subjects: 140
Study 36097940 — intervention group
Group type: EXPERIMENTAL
Intervention: 2SiO2‐1ZrO2
Number of subjects: 140
Study 36097940 — intervention group
Group type: COMPARATOR
Intervention: AS
Number of subjects: 140
Study 36097940 — intervention group
Group type: COMPARATOR
Intervention: 1SiO2‐4ZrO2
Number of subjects: 140
Study 36097940 — intervention group
Group type: COMPARATOR
Intervention: SB
Number of subjects: 140
Study 32676735 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reports
Number of subjects: 179
Study 32676735 — intervention group
Group type: COMPARATOR
Intervention: Freeform reports
Number of subjects: 179
Study 32755254 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg and folic acid 0.8 mg
Number of subjects: 14978
Study 32755254 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg alone
Number of subjects: 14978
Study 33951261 — intervention group
Group type: EXPERIMENTAL
Intervention: c-Met expression in colorectal cancer tissue
Number of subjects: 280
Study 33951261 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis of c-Met expression
Number of subjects: 280
Study 33951261 — intervention group
Group type: EXPERIMENTAL
Intervention: c-Met expression score of ≥14.50
Number of subjects: 280
Study 32651322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 209
Study 32651322 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 209
Study 35153152 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sterile water injections
Number of subjects: 238
Study 35153152 — intervention group
Group type: COMPARATOR
Intervention: Four sterile water injections
Number of subjects: 238
Study 34702280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouldering-Psychotherapy (BPT)
Number of subjects: 0
Study 34702280 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 32213470 — intervention group
Group type: EXPERIMENTAL
Intervention: internet‐based behavioral activation (iBA)
Number of subjects: 104
Study 32213470 — intervention group
Group type: COMPARATOR
Intervention: active control using a brief internet‐based mindfulness intervention (iMBI)
Number of subjects: 104
Study 32213470 — intervention group
Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 104
Study 35578051 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair
Number of subjects: 102
Study 35578051 — intervention group
Group type: COMPARATOR
Intervention: Robotic inguinal hernia repair
Number of subjects: 102
Study 33740276 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS, 125 mg/tab)
Number of subjects: 27